Rockefeller Capital Management
TXMD icon

Rockefeller Capital Management’s TherapeuticsMD TXMD Stock Holding History

Rockefeller Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-700
Closed -$25K – 3991
2021
Q3 		$25K Hold
700
– – ﹤0.01% 2493
2021
Q2 		$41K Hold
700
– – ﹤0.01% 2169
2021
Q1 		$46K Hold
700
– – ﹤0.01% 1924
2020
Q4 		$42K Hold
700
– – ﹤0.01% 1735
2020
Q3 		$55K Buy
+700
New +$55.8K ﹤0.01% 1480

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management's TXMD Position: Q4 2021 in Review

Rockefeller Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 700 shares — an estimated $25K sold.

Rockefeller Capital Management first reported a position in TXMD in Q3 2020 and held it in 5 quarters. The position peaked at $55K in Q3 2020. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

  • Rockefeller Capital Management reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 700 TherapeuticsMD shares in Q4 2021, an estimated $25K.
  • Rockefeller Capital Management first reported a position in TherapeuticsMD in Q3 2020 and held it in 5 quarters.
  • Rockefeller Capital Management's TherapeuticsMD position peaked at $55K in Q3 2020.
  • 131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Rockefeller Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.